Grass City 20% OFF

Insys Therapeuti (NASDAQ:INSY) is one of today’s worst performing low-priced stocks, down 69.7% to $1.09 on 1.5x average daily volume. Thus far today, Insys Therapeuti has traded 631,000 shares, vs. average volume of 412,000 shares per day. The stock has underperformed the Dow (-69.7% to the Dow’s -1.1%) and underperformed the S&P 500 (-69.7% to the S&P’s -1.1%) during today’s trading.

In the past 52 weeks, Insys Therapeuti share prices have been bracketed by a current low of $1.09 and a high of $11.65 and are now at $1.09. In the last five trading sessions, the 50-day moving average (MA) has fallen 4.4% while the 200-day MA has slid 1.5%.

Insys Therapeutics, Inc. develops cancer support drugs. The Company support care candidates include a fast-acting sublingual spray for cancer pain and a dronabinol product used to treat chemotherapy-induced nausea and vomiting and to stimulate appetite in AIDS patients.

Potential upside of 744.0% exists for Insys Therapeuti, based on a current level of $1.09 and analysts’ average consensus price target of $9.20. The stock should run into initial resistance at its 50-day moving average (MA) of $4.68 and subsequent resistance at its 200-day MA of $6.18.

SmarTrend recommended that its subscribers protect gains by selling shares of Insys Therapeuti on March 8th, 2019 by issuing a Downtrend alert when the shares were trading at $5.15. Since that call, shares of Insys Therapeuti have fallen 30.0%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.

Write to SmarTrend at


SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at:

Stock Symbols

Leave a Reply

Your email address will not be published. Required fields are marked *